Casgevy (exagamglogene autotemcel) is the first CRISPR-based medicine routinely commissioned on the NHS. NICE recommended it for severe sickle cell disease in technology appraisal TA1059 and for transfusion-dependent beta thalassaemia in TA1050, with delivery through a small number of specialist NHS centres. Treated patients are few in absolute numbers, but for community pharmacy the handful who return home after the procedure represent a step change in how long-term haemoglobinopathy medication is managed.
This piece sets out what the evidence says, what a treated patient's medication profile is likely to look like when they reach a community counter, and where the safe-supply red flags sit.
What Casgevy actually does
Exa-cel is a one-off autologous therapy. The patient's own haematopoietic stem cells are collected, edited ex vivo at the BCL11A erythroid enhancer to reactivate fetal haemoglobin, and reinfused after myeloablative conditioning with busulfan. In the pivotal CLIMB trials, the majority of treated patients with sickle cell disease were free of vaso-occlusive crises at two years, and most transfusion-dependent beta thalassaemia patients became transfusion-independent. NICE accepted these outcomes as clinically meaningful while acknowledging that long-term durability data continue to accrue.
The treatment is curative in intent, but a treated patient is not a patient without medicines. The myeloablative conditioning, the transition off chronic disease-modifying therapy, and the underlying disease burden all produce a recognisable post-treatment medication footprint.
What changes on the community pharmacy record
Hydroxycarbamide. In sickle cell disease, hydroxycarbamide is the mainstay disease-modifying therapy for patients with recurrent crises. Post-exa-cel, clinicians commonly taper and stop hydroxycarbamide once engraftment and fetal haemoglobin response are confirmed. A community pharmacy seeing an unexpected script change for a previously stable hydroxycarbamide patient — particularly a discontinuation — should not assume error; it may reflect a completed gene therapy pathway. Always verify with the prescribing centre rather than dispensing what was on the last repeat.
Iron chelation. Transfusion-dependent beta thalassaemia patients typically carry heavy iron burdens managed with deferasirox, deferiprone or desferrioxamine. After successful exa-cel, transfusion need falls away, but total body iron does not. Chelation usually continues for a protracted period, guided by ferritin and cardiac and hepatic MRI. Expect chelation prescriptions to continue for some time after the patient stops needing transfusions.
Folic acid. Routine folic acid 5 mg supplementation, common in both conditions, is typically reviewed post-treatment. It is usually continued during the early engraftment period and may be stepped down later.
Opioid analgesia. Patients with established sickle cell disease often have longstanding opioid prescriptions for breakthrough crisis pain. Post-treatment reduction of crisis frequency can mean analgesia requirements drop sharply, but opioid tapering must be clinician-led and gradual. Community pharmacy should flag any abrupt unsupervised dose changes to the specialist centre rather than adjusting at the counter.
Vaccination after myeloablative conditioning
Busulfan-based myeloablative conditioning effectively resets the immune system. NHS England's specialised commissioning pathway mandates a full post-transplant revaccination schedule, typically commencing at 6 to 12 months post-infusion. A treated patient is likely to receive repeated primary doses of diphtheria, tetanus, pertussis, polio, Hib, meningococcal and pneumococcal vaccines, alongside MMR and varicella where appropriate and once immune reconstitution allows. Community pharmacy teams running NHS vaccination services should not assume a previous vaccination history is protective. Always check against the patient's specialist-centre record.
Infection-prophylaxis medicines
During the period of immune reconstitution, patients commonly carry prophylactic antivirals such as aciclovir and antibacterial cover such as co-trimoxazole for Pneumocystis jirovecii pneumonia prophylaxis. These are usually specialist-initiated with community pharmacy dispensing against a hospital-issued prescription or shared-care arrangement. The typical duration is months, not years; review dates on the chart matter.
Fertility and contraception
Myeloablative conditioning carries a high risk of infertility. Pre-treatment gamete preservation is part of the pathway. Post-treatment, clinicians will usually have counselled the patient on contraception and family planning. Community pharmacy consultations about contraception with a post-exa-cel patient should be handled sensitively and, where relevant, in conversation with the specialist team.
What to watch for at the counter
| Signal | Suggested action |
|---|---|
| Unexpected hydroxycarbamide stop or dose reduction | Verify with specialist centre before dispensing or challenging |
| New iron chelator plus no recent transfusion history on the record | Consistent with post-exa-cel beta thalassaemia management |
| MMR, varicella or pneumococcal revaccination requested at unusual age | Check for post-transplant revaccination schedule |
| Dramatic opioid-requirement change | Do not escalate or de-escalate without specialist sign-off |
The broader sector picture
Community pharmacy workload is already under pressure. PharmSee tracks around 1,651 live UK pharmacy vacancies across eleven public sources as of 14 April 2026, with NHS Jobs alone accounting for 452 of those roles (see the PharmSee jobs board). Highly specialised therapy aftercare adds complexity that the typical counter interaction was not originally designed for, and it reinforces the argument for direct communication channels between specialist centres and a patient's nominated community pharmacy.
Caveats
Casgevy is delivered at a small number of specialist centres in England and Scotland. Absolute treated patient numbers remain low — likely in the low hundreds across the UK rather than the thousands. This article describes the medication footprint a community pharmacy may encounter, not a typical workload. For patient-specific advice, community pharmacy teams should liaise with the specialist centre named on the patient's hospital discharge record.
Sources
- NICE TA1059: Exagamglogene autotemcel for treating severe sickle cell disease.
- NICE TA1050: Exagamglogene autotemcel for treating transfusion-dependent beta thalassaemia.
- NHS England Specialised Commissioning pathways for haemoglobinopathies.
- PharmSee live jobs-board data, 14 April 2026.